Class of Stock [Axis] Common Stock 0.0001 Par Value Per Share [Member] Warrants To Purchase One Share Of Common Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Noncontrolling Interest [Member] Investment, Name [Axis] EBIR, Inc [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Accounts Payable [Member] Customer [Axis] Customer [Member] Product and Service [Axis] MPAR [Member] TAAP/OUD [Member] Antidilutive Securities [Axis] Share-Based Payment Arrangement, Option [Member] Warrant [Member] Convertible Debt Securities [Member] Consultant Shares [Member] Conversions From Preferred Stock [Member] Litigation Case [Axis] Consultant Dispute [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Galephar Agreement [Member] Statement Of Income Location [Axis] Research and Development Expenses [Member] Debt Instrument [Axis] 2023 Notes [Member] Financed Insurance [Member] Title and Position [Axis] Investors [Member] Board Member [Member] First Closing Securities Purchase Agreement [Member] Second Closing Securities Purchase Agreement [Member] Securities Purchase Agreement [Member] Series B Preferred Stock [Member] Inducement Letter [Member] Unregistered Warrant [Member] Common Warrants [Member] Statistical Measurement [Axis] Maximum [Member] Warrant One [Member] Warrant Two [Member] Registered Direct Offering [Member] Prefunded Warrant [Member] Series A Five Warrants [Member] Series A Six Warrants [Member] Preferred Class B [Member] Award Type [Axis] Minimum [Member] Warrant Three [Member] Warrant Four [Member] Warrant Five [Member] Warrant Six [Member] Warrant Seven [Member] Warrants One [Member] Class of Warrant or Right [Axis] Placement Agent Warrants [Member] Warrants Two [Member] Institutional Investor [Member] Investor Warrants [Member] Series B Warrants [Member] Series A Warrants [Member] Public Warrant [Member] Plan Name [Axis] 2021 Omnibus Incentive Plan [Member] General and Administrative Expenses [Member] Stock Option Available For Future Grant Under 2021 Omnibus Incentive Plan [Member] Warrant Outstanding [Member] Consultant Compensation Agreements [Member] Conversion of Series B Preferred Stock [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Assets Current assets: Cash and cash equivalents Unbilled receivable Prepaid expenses and other current assets Total current assets Property and equipment, net Other assets Total assets Liabilities and stockholders’ equity (deficit) Current liabilities: Accounts payable Accrued expenses and other liabilities Notes payable and accrued interest Total current liabilities Total liabilities Commitments and contingencies (Note 6) Stockholders’ equity (deficit) Preferred stock, $0.0001 par value, 1,500,000 shares authorized at March 31, 2026 and December 31, 2025; 4,000 shares issued at March 31, 2026 and December 31, 2025; 1,405 and 3,305 shares outstanding at March 31, 2026 and December 31, 2025, respectively; $1,545,500 and $3,635,500 liquidation preference at March 31, 2026 and December 31, 2025, respectively Common stock, $0.0001 par value, 250,000,000 shares authorized at March 31, 2026 and December 31, 2025; 9,277,825 and 4,574,983 shares issued at March 31, 2026 and December 31, 2025, respectively; 9,277,819 and 4,574,977 shares outstanding at March 31, 2026 and December 31, 2025, respectively Additional paid-in capital Accumulated deficit Total Ensysce Biosciences, Inc. stockholders’ equity (deficit) Noncontrolling interests in stockholders’ equity (deficit) Total stockholders’ equity (deficit) Total liabilities and stockholders’ equity (deficit) Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Preferred stock, liquidation preference value Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Federal grants Operating expenses: Research and development General and administrative Total operating expenses Loss from operations Other income (expense): Change in fair value of liability classified warrants Interest expense, net Other income and expense, net Total other income (expense), net Net loss Net loss attributable to common stockholders Net loss per basic and diluted share: Net loss per share attributable to common stockholders, basic Net loss per share attributable to common stockholders, diluted Weighted average common shares outstanding, basic Weighted average common shares outstanding, diluted Balance Balance, shares Public offering Public offering, shares Issuance of common stock upon exercise of warrants Issuance of common stock upon exercise of warrants, shares Transaction costs associated with public offering Consultant compensation Stock-based compensation Net loss Conversions of preferred stock into common stock Conversions of preferred stock into common stock, shares Transaction costs associated with Series B Preferred Stock Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Accrued interest Change in fair value of liability classified warrants Consultant compensation Stock-based compensation Depreciation expense Changes in operating assets and liabilities: Unbilled receivable Prepaid expenses and other assets Accounts payable Accrued expenses and other liabilities Net cash used in operating activities Cash flows from financing activities: Proceeds from public offerings Proceeds from warrant exercises Transaction costs from public offerings Repayment of financed insurance premiums Net cash (used in) provided by financing activities Decrease in cash and cash equivalents Cash and cash equivalents beginning of period Cash and cash equivalents end of period Supplemental disclosure of non-cash financing activities: Transaction costs included in accounts payable Accounting Policies [Abstract] ORGANIZATION AND PRINCIPAL ACTIVITIES Organization, Consolidation and Presentation of Financial Statements [Abstract] BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] PREPAID EXPENSES AND OTHER CURRENT ASSETS Payables and Accruals [Abstract] ACCRUED EXPENSES AND OTHER LIABILITIES Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Debt Disclosure [Abstract] NOTES PAYABLE Equity [Abstract] STOCKHOLDERS’ EQUITY Share-Based Payment Arrangement [Abstract] STOCK-BASED COMPENSATION Related Party Transactions [Abstract] RELATED PARTIES Subsequent Events [Abstract] SUBSEQUENT EVENTS Use of Estimates and Assumptions Cash and Cash Equivalents Concentrations of Credit Risk and Off-Balance Sheet Risk Segments Property and Equipment Fair Value Measurement Federal Grants Research and Development Costs General and Administrative Expenses Stock-based Compensation Income Taxes Earnings (loss) per Share Recently Issued Accounting Pronouncements Reclassification SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS SCHEDULE OF UNBILLED RECEIVABLE SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES SCHEDULE OF DEBT SCHEDULE OF CONVERTIBLE PREFERRED STOCK SCHEDULE OF OUTSTANDING WARRANT SCHEDULE OF STOCK OPTION ACTIVITY SCHEDULE OF COMMON STOCK FUTURE ISSUANCE AccountingPoliciesTable [Table] Ownership percentage Nature of Operation, Product Information, Concentration of Risk [Table] Product Information [Line Items] Total Unbilled receivable - beginning Unbilled receivable - ending Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total Concentration of risk, description Concentration of risk Number of operating segments Number of reportable segments Property and equipment, estimated useful life Property and equipment Grants receivable Prepaid research and development Prepaid insurance Other prepaid expenses Other current assets Total prepaid expenses and other current assets Accrued research and development Accrued consultant compensation Accrued professional fees Other accrued liabilities Total accrued expenses and other liabilities Loss Contingencies [Table] Loss Contingencies [Line Items] StatementOfIncomeLocationAxis [Axis] Contractual obligation Shares issued for settlement Accrued settlement value Number of restricted shares commited to issue Percentage of shares outstanding Stock based compensation Shares vesting upon grant date Vesting shares issued and outstanding Payments agreement description Shares issued for milestone awards Future lease payments Rent expense Short-Term Debt [Table] Short-Term Debt [Line Items] Principal balance Accrued interest Net debt balance Interest expense Interest expense Aggregate purchase price Aggregate principal amount Warrants to purchase common shares Warrant, exercise price Conversion of shares Conversion of shares value Transaction cost Warrant inducement cost Transaction cost Senior secured convertible promissory notes Financed insurance premiums Stock, Class of Stock [Table] Class of Stock [Line Items] Shares Issued Shares Outstanding Net Carrying Value Aggregate Liquidation Preference Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Outstanding warrant Exercise price Warrant description Warrant exercise price Warrants issued Warrant expiration date Warrant exercised Class of warrant or right, outstanding Warrant expiration date Common stock, gross proceeds Additional purchase Purchase of shares through securities purchase agreement Convertible shares Purchase of warrants Exercise price Preferred stock, dividends rate, percentage Preferred stock, conversion percentage Preferred stock, conversion price Conversion price description Conversion price percentage :Conversion triggering event price Exchange right percentage Gross proceeds Number of warrants exercisable Warrants term Legal fees Warrant maturity date Common stock , share price Agent fees and offering expenses , per share Option outstanding, beginning balance Weighted average exercise price. beginning balance Weighted average remaining contractual term Aggregate intrinsic value, beginning balance Option outstanding, granted Weighted average exercise price, granted Aggregate intrinsic value, granted Option outstanding, exercised Weighted average exercise price, exercised Aggregate intrinsic value, exercised Option outstanding, expired or forfeited Weighted average exercise price, expired / forfeited Aggregate intrinsic value, expired or forfeited Option outstanding, ending balance Weighted average exercise price, ending balance Aggregate intrinsic value, ending balance Option, exercisable Weighted average exercise price, exercisable Weighted average remaining contractual term, exercisable Aggregate intrinsic value, Exercisable Option vested or expected to vest Weighted average exercise price, vested or expected to vest Weighted average remaining contractual term, vested and expected to vest Aggregate intrinsic value, vested or expected to vest Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Total shares of common stock reserved for future issuance Common stock, capital shares reserved for future issuance Share based compensation expense Unrecognized stock based compensation Weighted average period RelatedPartyTransactionsTable [Table] Debt financing amount Warrants exercisable Warrant, expiration date Subsequent Event [Table] Subsequent Event [Line Items] Shares issued Purchase of warrant Number of shares issued Conversion of shares Debt conversion price Gross proceeds Exerciseable term Preferred stock, stated value Warrants to Purchase on Share of Common Stock [Member] Common Stock 0.0001 Par Value Per Share [Member] Change in fair value of liability classified warrants. Stock issued during period issuance of common stock upon exercise of warrants. Stock issued during period issuance of common stock upon exercise of warrants, shares. Stock issued during period value conversions of preferred stock into common stock. Transaction costs associated with Series B Preferred Stock. Stock issued during period shares conversions of preferred stock into common stock. Stock issued during period value consultant compensation. Changes in unbilled receivable. Repayment of financed insurance premiums. EBIR, Inc [Member] Customer [Member] Federal Grants [Policy Text Block] Schedule of Revenue Recognition Under Grants [Table Text Block] Schedule of Unbilled Receivable [Table Text Block] Conversions From Preferred Stock [Member] Prepaid research and development. Accrued research and development. Accrued consultant compensation. Consultant Dispute [Member] Galephar Agreement [Member] Percentage of shares outstanding. Payments agreement description. Research and Development Expenses [Member] 2023 Notes [Member] Financed Insurance [Member] Board Member [Member] First Closing Securities Purchase Agreement [Member] Second Closing Securities Purchase Agreement [Member] Proceeds from warrant inducement, net of issuance costs. Securities Purchase Agreement [Member] Transaction costs associated with warrant inducement. Issuance of common stock value upon warrant inducement, net of issuance costs. Financed insurance premiums. Preferred stock carrying value. Conversion price triggering event percentage. Conversion price triggering event price. Exchange right percentage. Inducement Letter [Member] Unregistered Warrant [Member] Share based compensation arrangement by share based payment award non option equity instruments exercisable. Common Warrants [Member] Warrant One [Member] Warrant Two [Member] Registered Direct Offering [Member] Prefunded Warrant [Member] Agent fees and offering expenses per share. Series A Five Warrants [Member] Series A Six Warrants [Member] Warrant Three [Member] Warrant Four [Member] Warrant Five [Member] Warrant Six [Member] Warrant Seven [Member] Exercise price. Warrant Description. Warrants One [Member] Placement Agent Warrants [Member] Warrants Two [Member] Institutional Investor [Member] Investor Warrants [Member] Series A Warrants [Member] Series B Warrants [Member] Public Warrant [Member] 2021 Omnibus Incentive Plan [Member] General and Administrative Expenses [Member] Share based compensation arrangement by share based payment award options vested and expected to vest weighted average remaining contractual term. Total Intrinsic value of share based payment forfeiture and expiration. Schedule Of Common Stock Future Issuance [Table Text Block] Stock Option Available For Future Grant Under 2021 Omnibus Incentive Plan [Member] Warrant Outstanding [Member] Consultant Compensation Agreements [Member] Conversion of Series B Preferred Stock [Member] Warrant or right exercisable. Statement of Income Location Axis MPAR [Member] TAAP/OUD [Member] Consultant Shares [Member] Transaction costs from public offerings. Transaction Costs under accounts payable. Adjustments to additional paid in capital, transaction costs associated with public offering. Investors [Member] Warrants and rights outstanding maturity date description. Warrants To Purchase One Share Of Common Stock [Member] Assets, Current Assets [Default Label] Liabilities, Current Liabilities Equity, Attributable to Parent Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense, Nonoperating Nonoperating Income (Expense) Net Income (Loss) Available to Common Stockholders, Basic Shares, Outstanding ConsultantCompensation IncreaseDecreaseInUnbilledReceivable Increase (Decrease) in Prepaid Expenses, Other Increase (Decrease) in Accounts Payable Increase (Decrease) in Other Accrued Liabilities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation TransactionCostsFromPublicOfferings RepaymentInsurancePremiums Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Accrued Liabilities and Other Liabilities Interest Payable Interest Expense, Operating and Nonoperating TransactionCostsAssociatedWithWarrantInducement WarrantsAndRightsOutstandingMaturityDateDescription Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Conversion of Stock, Shares Converted Proceeds from Issuance of Common Stock